8-Methyl-pyrido<2.3-d>pyridazin | 19818-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 8-Methyl-pyrido<2.3-d>pyridazin
• 英文别名: 8-Methylpyrido[2,3-d]pyridazine
• CAS: 19818-97-4
• 化学式: C₈H₇N₃
• 分子量: 145.164
• InChiKey: FBXNFALUPYLREY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIDIABÉTIQUES CONTENANT DE LA PHTALAZINE
  申请人：SCHERING CORP

  公开号：WO2010091176A1

  公开（公告）日：2010-08-12

  This invention provides for certain phthalazine-containing compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein G is an optionally substituted N-N containing heteroaryl group and the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

  这项发明提供了具有以下结构的某些含有邻苯二氮杂环烷基的化合物（I）或其药用可接受的盐、酯或溶剂，其中G是一个可选择取代的N-N含杂芳基团，变量在此处定义；这些创新化合物是G蛋白偶联受体40（GPR40，也称为游离脂肪酸受体FFAR）的激动剂。该发明还涉及含有这些化合物的药物组合物，并且利用这些化合物在哺乳动物中调节胰岛素水平。这些化合物可以用于预防和治疗2型糖尿病，以及预防和治疗与2型糖尿病相关的疾病，如胰岛素抵抗、肥胖和脂质紊乱。
• Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity
  申请人：Arizona Board of Regents

  公开号：US11245078B2

  公开（公告）日：2022-02-08

  Thermally activated delayed fluorescent compounds and uses thereof are described. The thermally activated delayed fluorescent compounds are an analogues of 9,10-dihydro-9,9-dimethylacridine compounds.

  本文描述了热激活延迟荧光化合物及其用途。这些热激活延迟荧光化合物是9,10-二氢-9,9-二甲基蒽嗪化合物的类似物。
• RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3064582A1

  公开（公告）日：2016-09-07

  An object to be solved by the present invention is to identify patients resistant to known HSP90 inhibitors, and to provide a novel therapeutic agent for treating the patients who have become resistant to known HSP90 inhibitors. As a means for solving the above problems, the present invention provides identification of the patients based on a protein, which is an HSP90 family protein having a mutation in the site corresponding to F138 of HSP90α class A consisting of the amino acid sequence of SEQ ID NO: 1, and use of a substance that inhibits the protein as an active ingredient of a therapeutic agent.

  本发明要解决的一个目的是鉴定对已知HSP90抑制剂耐药的患者，并提供一种新型治疗剂用于治疗对已知HSP90抑制剂耐药的患者。 作为解决上述问题的一种方法，本发明提供了基于一种蛋白质识别患者的方法，该蛋白质是一种在由SEQ ID NO: 1的氨基酸序列组成的HSP90α类A的F138对应位点发生突变的HSP90家族蛋白质，以及使用抑制该蛋白质的物质作为治疗剂的有效成分。
• PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS
  申请人：Davis Jason L.

  公开号：US20120004234A1

  公开（公告）日：2012-01-05

  This invention provides for certain phthalazine-containing compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein G is an optionally substituted N—N containing heteroaryl group and the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.
• Thermally Activated Delayed Fluorescent Material Based on 9,10-Dihydro-9,9-dimethylacridine Analogues for Prolonging Device Longevity
  申请人：Arizona Board of Regents on behalf of Arizona State University

  公开号：US20170077420A1

  公开（公告）日：2017-03-16

  Thermally activated delayed fluorescent compounds and uses thereof are described. The thermally activated delayed fluorescent compounds are an analogues of 9,10-dihydro-9,9-dimethylacridine compounds.

表征谱图